相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
N Waugh et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
M. A. Nauck et al.
DIABETOLOGIA (2011)
On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Meena Asmar et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
Mark Kirby et al.
CLINICAL SCIENCE (2010)
Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study
Sabine Arnolds et al.
DIABETES CARE (2010)
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
M. Ligueros-Saylan et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
Andre J. Scheen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
The dipeptidyl peptidase IV family in cancer and cell biology
Denise M. T. Yu et al.
FEBS JOURNAL (2010)
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
S. S. Engel et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Presence of a Functional Receptor for GLP-1 in Osteoblastic Cells, Independent of the cAMP-Linked GLP-1 Receptor
Bernardo Nuche-Berenguer et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis
Detlef Schuppan et al.
LIVER INTERNATIONAL (2010)
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
Robert Frederich et al.
POSTGRADUATE MEDICINE (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction
Marc-Michael Zaruba et al.
CELL STEM CELL (2009)
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
David D. Dore et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Beta cell mass in diabetes: a realistic therapeutic target?
J. J. Meier
DIABETOLOGIA (2008)
Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas
J. de Heer et al.
DIABETOLOGIA (2008)
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption
Chizumi Yamada et al.
ENDOCRINOLOGY (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide
Dariush Elahi et al.
OBESITY (2008)
Effect of renal impairment on the pharmacokinetics of exenatide
Helle Linnebjerg et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
GLP-1 receptor expression in human tumors and human normal tissues:: Potential for in vivo targeting
Meike Koerner et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1
Kei Ohnuma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
George G. Sokos et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Caveolin-1 regulates cellular trafficking and function of the glucagon-like peptide 1 receptor
Colin A. Syme et al.
MOLECULAR ENDOCRINOLOGY (2006)
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
A. Barnett
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice
Laurie L. Baggio et al.
DIABETES (2006)
The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
JJ Meier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs
L Simonsen et al.
DIABETOLOGIA (2006)
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
LA Nikolaidis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
What do we know about the secretion and degradation of incretin hormones?
CF Deacon
REGULATORY PEPTIDES (2005)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
JJ Meier et al.
DIABETES (2004)
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
T Vilsboll et al.
REGULATORY PEPTIDES (2003)
Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
OG Kolterman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
JJ Meier et al.
DIABETOLOGIA (2003)
The influence of GLP-1 on glucose-stimulated insulin secretion -: Effects on β-cell sensitivity in type 2 and nondiabetic subjects
LL Kjems et al.
DIABETES (2003)
The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion
PE MacDonald et al.
DIABETES (2002)
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsboll et al.
DIABETOLOGIA (2002)
Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and-4
A Thum et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2002)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
Ernest Starling and the discovery of secretin
IM Modlin et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2001)
Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
CF Deacon et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)